Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar rossklaw (< 20) Submitted: 10/3/2011 11:52:10 PM : Outperform Start Price: $1.41 AEZS Score: -87.21

Pipeline gamble

Report this Post Reply

Featured Broker Partners


Advertisement